Ginkgo Bioworks Holdings (DNA) Change in Receivables (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Change in Receivables came in at $242000.0 in Q1 2026, down 63.72% YoY from $667000.0 in Q1 2025, and down 86.69% on a QoQ basis from $1.8 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Change in Receivables (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Change in Receivables data on file, last reported at $242000.0 in Q1 2026.
- Quarterly Change in Receivables fell 63.72% year-over-year to $242000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (up 176.05% YoY) and the FY2025 annual result came in at $1.5 million, down 68.83% from the prior year.
- Change in Receivables fell to $242000.0 in Q1 2026, from $1.8 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $6.8 million in Q1 2024 to a low of -$34.5 million in Q4 2022.
- A 5-year average of -$5.6 million and a median of -$506000.0 in 2025 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2022 — Change in Receivables plunged 140.0% — and 2024, when it jumped 1187.07%.
- Tracing DNA's Change in Receivables over 5 years: stood at -$34.5 million in 2022, then grew by 16.24% to -$28.9 million in 2023, then soared by 95.24% to -$1.4 million in 2024, then jumped by 232.12% to $1.8 million in 2025, then plunged by 86.69% to $242000.0 in 2026.
- The last three Change in Receivables figures came in at $242000.0 (Q1 2026), $1.8 million (Q4 2025), and -$757000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | -3.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.71 Mn |
| Jun 30, 2026 | -3.71 Mn |
| Mar 31, 2026 | 242,000.00 |
| Mar 31, 2026 | 242,000.00 |
| Dec 31, 2025 | 1.82 Mn |
| Dec 31, 2025 | 1.82 Mn |
| Sep 30, 2025 | -757,000.00 |
| Sep 30, 2025 | -757,000.00 |
| Jun 30, 2025 | -255,000.00 |
| Jun 30, 2025 | -255,000.00 |
| Mar 31, 2025 | 667,000.00 |
| Mar 31, 2025 | 667,000.00 |
| Dec 31, 2024 | -1.38 Mn |
| Dec 31, 2024 | -1.38 Mn |
| Sep 30, 2024 | 5.00 Mn |
| Sep 30, 2024 | 5.00 Mn |
| Jun 30, 2024 | -5.67 Mn |
| Jun 30, 2024 | -5.67 Mn |
| Mar 31, 2024 | 6.77 Mn |
| Mar 31, 2024 | 6.77 Mn |